United States HIV/AIDS Therapeutic Markets

 


Availability: In stock

 

Regular Price: USD 3,950

Special Price USD 2,765

* Required Fields

Regular Price: USD 3,950

Special Price USD 2,765

PAY BY INVOICE

Be the first to review this product

Table of Contents

United States HIV/AIDS Therapeutic Markets, Executive SummaryIntroduction to the U.S. HIV/AIDS Therapeutics MarketObjectives and PurposeReport Scope and SegmentationReport Structure Summary of Major FindingsDrivers Affecting the Total U.S. HIV/AIDS Therapeutics MarketRestraints Affecting the Total U.S. HIV/AIDS Therapeutics MarketTotal Revenues and Revenue Growth RatesPercent of Revenues by Product TypeAnalysis by Major SegmentCompetitive AnalysisUnited States HIV/AIDS Therapeutic Markets, Market Engineering Research MethodologyFrost & Sullivan's Market Engineering Forecasting Methodology for the Healthcare IndustryFrost & Sullivan's Market Engineering Forecasting Methodology for the Healthcare IndustryResearch SourcesSecondary SourcesPrimary ResearchPharmaceutical Forecast ModelPharmaceutical Forecast ModelPopulation-Based ForecastMarket Model Assumptions Research LimitationsPresentation of Market Engineering Measurements; Definition and their Strategic SignificancePresentation of Market Engineering Measurements; Definition and their Strategic SignificanceGlossary of TermsGlossary of TermsUnited States HIV/AIDS Therapeutic Markets, Challenges in the U.S. HIV/AIDS Therapeutics MarketIdentification of Challenges Facingthe U.S. HIV/AIDS Therapeutics MarketIdentification of Challenges Facingthe U.S. HIV/AIDS Therapeutics MarketNeed for Simple Potent RegimensPenetrating Untapped Patient Population Boosts Market Share Improving Minor Side-Effect Profiles of Drugs Greatly Boosts ComplianceAttracting Treatment-Naive Patients Ensures Positive GrowthDevelopment of Resistance-Free Drugs Increase UptakeMaximizing Patient Enrollment in Clinical Trials Attracts Potential End UsersNeed for Clinical Trials Showing HIV Drugs Have No Interaction with Recreational DrugsOffering Combination Products Expedites Market GrowthLimiting Use of Protease Inhibitors Provides Strong Growth for NNRTIsSupporting Data Needed for New NNRTIs to Prevent CannibalizationMarket Engineering Research for the U.S. HIV/AIDS Protease Inhibitor (PI) Market Market Overview and DefinitionsOverviewDefinitionScope/SegmentationMarket Engineering Research Measurement SystemMarket Engineering Research Measurement SystemMarket DriversMarket RestraintsMarket Engineering Revenue Forecasts (1995-2005)Patient Population (Demand Analysis)Pricing AnalysisRevenuesCompetitive AnalysisCompetitive StructureMarket Share AnalysisMarket Share Winners and WhyMarket Share Losers and WhyProduct AnalysisProducts on the MarketProducts in Clinical TrialsMarket Engineering Research for the U.S. HIV/AIDS Nucleoside Reverse Transcriptase Inhibitor (NRTI) Market Market Overview and DefinitionsOverviewDefinitionScope/SegmentationHistoryMarket Engineering Research Measurement SystemMarket Engineering Research Measurement SystemMarket DriversMarket RestraintMarket Engineering Revenue Forecasts (1995-2005)Patient Population (Demand Analysis)Pricing AnalysisRevenuesCompetitive AnalysisCompetitive StructureMarket Share AnalysisMarket Share Winners and WhyMarket Share Losers and WhyProduct AnalysisProducts on the MarketProducts in Clinical TrialsMarket Engineering Research for the U.S. HIV/AIDS Non-Nucleoside Inhibitor Market Market Overview and DefinitionsOverviewDefinitionScope/SegmentationHistoryMarket Engineering Research Measurement SystemMarket Engineering Research Measurement SystemMarket DriversMarket RestraintsMarket Engineering Revenue Forecasts (1995-2005)Patient Population (Demand Analysis)Pricing AnalysisRevenuesCompetitive AnalysisCompetitive StructureMarket Share AnalysisMarket Share Winners and WhyMarket Share Losers and WhyProduct AnalysisProducts on the MarketProducts in Clinical TrialsProducts in DevelopmentUnited States HIV/AIDS Therapeutic Markets, Emerging HIV/AIDS TherapiesMarket Overview and DefinitionsOverviewEmerging Therapies by Product Class in Clinical TrialsUnited States HIV/AIDS Therapeutic Markets, Profiles of Strategically Targeted CompaniesProfiles of Strategically Targeted CompaniesProfiles of Strategically Targeted Companies




Related Research

Release Date : 24-Jul-17

Region : North America

Release Date : 11-Jul-17

Region : North America

Release Date : 21-Jun-17

Region : North America

Release Date : 29-May-17

Region : North America

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.